Nami Surgical

Cover Block

PUBLIC

Name	Nami Surgical
Tagline	Miniaturized ultrasonic surgical scalpels for robotic-assisted and minimally invasive surgery.
Headquarters	Glasgow, UK
Founded	2021
Stage	Seed
Business Model	Hardware + Software
Industry	Deeptech
Technology	Robotics
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed (total disclosed ~$4,050,000)

Links

PUBLIC

• Website: https://www.namisurgical.com/
• LinkedIn: https://uk.linkedin.com/in/nico-fenu

Data Accuracy: GREEN -- Confirmed by company website and LinkedIn profile.

Executive Summary

PUBLIC Nami Surgical is a Glasgow-based deeptech company building miniaturized ultrasonic scalpels designed to integrate with robotic-assisted surgery systems, a bet that hinges on improving surgical precision in a rapidly growing market [Nami Surgical, retrieved 2026]. Founded in 2021 as a spin-out from the University of Glasgow's Centre for Medical and Industrial Ultrasonics, the company's technology aims to provide a more maneuverable, high-performance tool for complex minimally invasive procedures, positioning it as a component supplier rather than a full-system robotics manufacturer [Nami Surgical, retrieved 2026].

The founding team combines technical and commercial expertise, with Dr. Rebecca Shirley Cleary as CTO and Dr. Nico Fenu as CEO, though the company recently appointed industry veteran Nikki Palfrey as CEO in January 2026 to lead its next growth phase [Nami Surgical, January 2026]. Funding to date is a mix of venture capital and public grants, with a confirmed £3.2 million raised in June 2024 and reports of a subsequent £1.9 million round in early 2026, though total capitalization figures conflict across sources [Nami Surgical, June 2024] [Preqin, February 2026]. The business model is hardware-focused, with revenue expected from the sale of its proprietary surgical instruments to medical device groups and healthcare systems.

Over the next 12-18 months, the key milestones to watch are the progression of its pilot programmes with unnamed medical device groups, the achievement of specific regulatory clearances for international expansion, and the clarification of its commercial traction beyond grant and investor funding [Social Investment Scotland, retrieved 2026].

Data Accuracy: YELLOW -- Core company details and recent funding are confirmed by primary sources; conflicting reports on total funding amounts and round specifics require corroboration.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Deeptech
Technology Type	Robotics
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed (total disclosed ~$4,050,000)

Company Overview

PUBLIC

Nami Surgical emerged in 2021 as a spin-out from the University of Glasgow’s Centre for Medical and Industrial Ultrasonics (C-MIU), translating academic research on ultrasonic technology into a commercial venture for surgical robotics [Nami Surgical, retrieved 2026]. The company’s founding premise, as articulated on its website, is that miniaturized ultrasonic instruments represent a missing component for the next generation of high-precision, minimally invasive robotic surgery [Nami Surgical, retrieved 2026].

Headquartered in Glasgow, the company’s development path is marked by a sequence of non-dilutive and venture capital financings. In June 2024, Nami Surgical announced a combined £3.2 million in capital, comprising a £2.5 million seed round led by Eos Advisory with participation from the Investment Fund for Scotland, and a separate £700,000 grant from Innovate UK [Nami Surgical, June 2024]. This round also saw the appointment of Albert Nicholl as Non-executive Director and Chair of the board [Nami Surgical, June 2024].

A significant leadership transition occurred in January 2026, when Nikki Palfrey was appointed CEO, succeeding co-founder Dr. Nico Fenu [Nami Surgical, January 2026]. Palfrey, who had served as a Non-executive Director since 2023, brings over 25 years of MedTech leadership experience to the role [rutlandherald.com, retrieved 2026]. Concurrent with this change, the company completed a further investment round, reported elsewhere as £1.9 million in February 2026 [Preqin, February 2026]. The founding team remains involved, with Dr. Rebecca Shirley Cleary as CTO and Dr. Nico Fenu continuing in a leadership capacity [Social Investment Scotland, retrieved 2026].

Data Accuracy: YELLOW -- Core founding and funding milestones are confirmed by the company's own announcements, though total funding figures conflict across secondary databases.

Product and Technology

MIXED Nami Surgical's core offering is a miniaturized ultrasonic scalpel, a hardware component designed to integrate with existing robotic-assisted surgery (RAS) platforms. The company's public positioning emphasizes the instrument's precision and maneuverability for complex tasks in confined, minimally invasive surgical environments [Nami Surgical]. This focus on a single, high-performance tool, rather than a full robotic system, defines its role as a component supplier within the broader surgical robotics ecosystem.

The technology is a spin-out from the University of Glasgow's Centre for Medical and Industrial Ultrasonics (C-MIU), anchoring its development in academic research [Nami Surgical]. Public materials describe an active development phase focused on prototype testing and verification to meet safety, reliability, and biocompatibility standards, a necessary precursor to clinical trials and regulatory submissions [Nami Surgical, December 2025]. The company has indicated it is running pilot programmes with unnamed healthcare and medical device groups, including in the United States, though no specific partners or commercial deployments have been publicly disclosed [Social Investment Scotland].

Data Accuracy: YELLOW -- Product claims are consistent across the company's website and primary announcements. Technical details and commercial deployment status are limited to company statements.

Market Research

PUBLIC The market for robotic-assisted surgery is not just expanding, it is structurally evolving from a focus on the robotic arms themselves to the specialized instruments that define their clinical utility, creating a new layer of opportunity for component innovators.

Third-party research firms consistently forecast robust growth for the underlying robotic surgery systems market, though specific valuations vary by methodology. Mordor Intelligence projects the market will reach $11.26 billion in 2025, growing at a 13.54% CAGR to $21.25 billion by 2030 [Mordor Intelligence, retrieved 2026]. Straits Research offers a more aggressive forecast, valuing the market at $12.62 billion in 2025 and projecting a 16.9% CAGR to $44.04 billion by 2033 [Straits Research, retrieved 2026]. Other analysts, including Towards Healthcare and MDDI Online, provide similar mid-to-high teens compound annual growth rates over the next decade, with projections ranging from $16.4 billion by 2030 to $63.73 billion by 2035 [MDDI Online, retrieved 2026] [Towards Healthcare, retrieved 2026]. These figures establish a clear, high-growth context for any company operating in the surgical robotics ecosystem.

The primary demand drivers cited across these reports are well-established. An aging global population increases the volume of complex surgical procedures, particularly in oncology and orthopedics. Concurrently, a persistent shortage of specialized surgeons creates pressure to enhance individual surgeon productivity and precision. Healthcare systems are increasingly focused on value-based care, where robotic-assisted procedures can contribute to better patient outcomes, shorter hospital stays, and lower readmission rates, justifying the capital expenditure. Finally, technological advancements in imaging, data integration, and miniaturization are continuously expanding the feasible applications for robotic systems beyond their initial domains.

Nami Surgical's specific addressable market is a subset of this broader landscape, focused on the instruments and accessories segment. While the company cites a $9 billion market size for robotic-assisted surgery [Nami Surgical, retrieved 2026], this appears to be a general market figure rather than a serviceable market calculation for ultrasonic scalpels. The instrument segment is typically a smaller, though still significant, portion of the total system market. Adjacent and substitute markets include traditional laparoscopic instruments, advanced energy devices (like electrosurgical tools), and other emerging modalities for tissue dissection. A key macro force is the regulatory pathway; bringing a new Class II or III medical device to market in the US (FDA) and Europe (MDR) requires substantial time and capital for clinical validation and quality system compliance, a hurdle noted in the company's own commentary on preparing for multiple regulatory systems [Nami Surgical, December 2025].

Market Size 2024 | 9.1 | $B
Market Size 2025 | 12.62 | $B
Projected Size 2030 | 21.25 | $B
Projected Size 2033 | 44.04 | $B

The chart synthesizes third-party market size estimates, illustrating the consensus on strong double-digit growth. The jump from 2024 to 2025 figures highlights the variance between different analyst baselines, but the long-term trajectory is uniformly upward.

Data Accuracy: GREEN -- Market sizing and growth rates are corroborated by multiple independent analyst reports (Mordor Intelligence, Straits Research, MDDI Online, Towards Healthcare). The company's own $9Bn market claim is noted as a single-source assertion.

Competitive Landscape

MIXED Nami Surgical enters a market defined by large, integrated system vendors, positioning itself not as a robotics platform competitor but as a specialized component supplier for high-precision ultrasonic dissection.

The competitive map is stratified by business model and scope of integration. At the top are the dominant system integrators, whose primary business is selling complete robotic surgery platforms and the associated instruments.

Intuitive Surgical | 155.3 | $B
Stryker Corporation | 53.6 | $B
Medtronic | 77.5 | $B
Johnson & Johnson | 381.6 | $B
Zimmer Biomet | 29.4 | $B

These figures represent enterprise valuations, illustrating the scale of capital and market presence Nami faces in its potential partners and customers. The competitive dynamic is less about head-to-head replacement and more about securing a slot within these established ecosystems.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Nami Surgical	Supplier of miniaturized ultrasonic scalpels for robotic-assisted surgery.	Seed; ~$4M+ disclosed (2024-2026).	Focus on ultrasonic precision within constrained robotic tool channels.	[Nami Surgical, retrieved 2026]
Intuitive Surgical	Dominant provider of integrated robotic surgery systems (da Vinci).	Public; $155B market cap.	Full-stack control of hardware, software, and instrument ecosystem.	[Public Filings]
Medtronic	Major medtech conglomerate with robotic platform (Hugo RAS).	Public; $77.5B market cap.	Broad portfolio enabling bundled sales and clinical workflow integration.	[Public Filings]
Stryker Corporation	Leader in surgical robotics for orthopedics (Mako system).	Public; $53.6B market cap.	Deep specialization in bone-borne applications and orthopedic data.	[Public Filings]

The company's defensible edge today is rooted in its academic origin and the specific physics of its technology. As a spin-out from the University of Glasgow's Centre for Medical and Industrial Ultrasonics, Nami's initial intellectual property and engineering talent are tied to a recognized research hub [Nami Surgical, retrieved 2026]. The technical differentiator is the miniaturization of ultrasonic cutting and coagulation into a form factor suitable for the narrow tool channels of robotic systems, a niche not fully addressed by the electrosurgical instruments that dominate current robotic tool sets. This edge is perishable, however, as it relies on maintaining a development lead before larger incumbents dedicate internal R&D resources to a similar form factor or acquire a competing specialist.

Nami's most significant exposure is to the distribution and integration moats owned by the system vendors. Intuitive Surgical, for example, maintains a proprietary instrument ecosystem for its da Vinci platform, with stringent certification processes for third-party tools [Public Filings]. Gaining traction requires not just technical validation but also commercial partnerships and regulatory clearance specific to each robotic platform, a channel Nami does not own. Furthermore, adjacent substitutes exist in the form of advanced energy devices from companies like Ethicon (a Johnson & Johnson company) or Olympus, which could be adapted for robotic use, competing on the basis of existing surgeon familiarity and bulk purchasing agreements.

The most plausible 18-month scenario involves Nami progressing from pilot programs to a formal partnership with one major robotics vendor for a specific surgical application [Social Investment Scotland, retrieved 2026]. A winner in this scenario would be a mid-tier platform player like Medtronic, seeking to differentiate its Hugo system with a best-in-class ultrasonic tool to compete against Intuitive's dominance. A loser would be Nami itself if it fails to secure such a partnership and remains a science project, as the capital required for independent commercial scaling and direct sales to hospitals vastly exceeds its current funding runway.

Data Accuracy: YELLOW -- Competitor profiles are based on public company data; Nami's positioning is from its website. The competitive dynamics analysis is inferred from industry structure.

Opportunity

PUBLIC The core opportunity for Nami Surgical is to become the default supplier of high-precision ultrasonic instruments for the next generation of robotic surgery systems, a role that could be valued in the hundreds of millions if the company captures a meaningful share of a rapidly growing, multi-billion dollar market.

The headline opportunity is to establish a proprietary, component-level standard for ultrasonic dissection and coagulation within robotic-assisted surgery. Rather than building a full robotic system, Nami aims to supply the critical, high-performance tools that integrate into existing and future platforms. The evidence that this outcome is reachable, not merely aspirational, lies in the company's academic roots and early validation. As a spin-out from the University of Glasgow's Centre for Medical and Industrial Ultrasonics, the technology originates from a recognized research hub [Nami Surgical, retrieved 2026]. The company has secured multiple rounds of non-dilutive and venture funding from entities like Innovate UK and Eos Advisory, which typically require technical due diligence [Nami Surgical, June 2024]. This combination of deep technical provenance and institutional financial backing provides a plausible foundation for developing a component that meets the stringent performance and safety thresholds required for surgical robotics.

Multiple, concrete paths exist for Nami to achieve scale. The company's growth will likely be dictated by its ability to secure integration partnerships with major robotic platform manufacturers or to demonstrate clinical utility that drives adoption within leading hospital systems.

Scenario	What happens	Catalyst	Why it's plausible
Platform Partnership	Nami's ultrasonic scalpel becomes a preferred or exclusive instrument for a next-generation robotic surgery system.	A formal development and supply agreement with a large MedTech incumbent or a rising robotic surgery challenger.	The company is actively engaging with "healthcare and medical device groups worldwide" in pilot programmes, indicating business development activity aimed at such partnerships [Social Investment Scotland, retrieved 2026].
Procedure-Specific Dominance	The tool becomes the standard of care for a specific, complex minimally invasive procedure (e.g., thoracic or colorectal surgery) due to superior clinical outcomes.	Publication of positive clinical study data from an ongoing pilot programme, particularly in the United States [Social Investment Scotland, retrieved 2026].	The technology's stated focus on maneuverability and precision for complex tasks aligns with unmet needs in advanced laparoscopic and robotic procedures [Nami Surgical, retrieved 2026].

What compounding looks like for a component supplier is a combination of technical and commercial lock-in. Each successful integration creates a new dataset of clinical use and performance feedback, which informs iterative product improvements that competitors without real-world deployment cannot match. This creates a technical moat. Commercially, securing a design-win with a major platform manufacturer creates long-term, recurring revenue streams tied to that platform's instrument sales and procedure volumes. The company's recent focus on preparing for "multiple regulatory systems" suggests it is building the infrastructure to support this international, platform-driven scale [Nami Surgical, December 2025].

The size of the win can be framed by looking at the value of specialized instrument makers within the broader surgical robotics ecosystem. The global market for surgical robots was valued at $9.3 billion in 2024 [MDDI Online, retrieved 2026]. Instrument and accessory sales typically constitute a significant portion of a robotic system's lifetime revenue. If Nami were to capture a single-digit percentage share of the instrument segment within a market projected to reach $16.4 billion by 2030, its annual revenue opportunity would measure in the hundreds of millions of dollars [MDDI Online, retrieved 2026]. As a comparable, publicly traded pure-play surgical robotics companies often trade at significant revenue multiples due to high growth and gross margins. A successful execution of the Platform Partnership scenario could position Nami for an acquisition or public offering at a valuation that reflects its potential as a high-margin, recurring revenue business embedded in a growth market (scenario, not a forecast).

Data Accuracy: YELLOW -- The core opportunity framing is supported by company statements and market research. The specific growth scenarios are plausible inferences from disclosed pilot programmes but lack confirmation of named partners or clinical data.

Sources

PUBLIC

1. [Nami Surgical, retrieved 2026] Nami Surgical - Developing the future of surgical precision using ultrasonic technology | https://www.namisurgical.com/

2. [Nami Surgical, June 2024] June 2024 - Nami Surgical | https://www.namisurgical.com/2024/06/

3. [Nami Surgical, January 2026] Nami Surgical appoints Nikki Palfrey as CEO and completes latest investment round | https://www.namisurgical.com/

4. [Preqin, February 2026] Preqin report on Nami Surgical funding | https://app.dealroom.co/companies/nami_surgical

5. [Social Investment Scotland, retrieved 2026] Social Investment Scotland profile of Nami Surgical | https://www.socialinvestmentscotland.com/

6. [rutlandherald.com, retrieved 2026] Ultrasonic Surgery Specialist Nami Appoints Nikki Palfrey as CEO and Completes Latest Investment Round | https://www.rutlandherald.com/news/business/ultrasonic-surgery-specialist-nami-appoints-nikki-palfrey-as-ceo-and-completes-latest-investment-round/article_2f9bd021-50e8-5d0b-98d7-426eeaccb1b7.html

7. [Nami Surgical, December 2025] From Lab to Operating Theatre: How Prototype Testing Translates into Clinical Readiness | https://www.namisurgical.com/2025/12/04/from-lab-to-operating-theatre-how-prototype-testing-translates-into-clinical-readiness/

8. [Mordor Intelligence, retrieved 2026] Mordor Intelligence Robotic Assisted Surgery Systems Market Report | https://www.mordorintelligence.com/

9. [Straits Research, retrieved 2026] Straits Research Robotic-assisted Surgery Systems Market Report | https://straitsresearch.com/

10. [MDDI Online, retrieved 2026] MDDI Online Surgical Robotics Market Report | https://www.mddionline.com/

11. [Towards Healthcare, retrieved 2026] Towards Healthcare Robotic Surgery Market Report | https://www.towardshealthcare.com/

12. [Public Filings] Intuitive Surgical Annual Report | https://investor.intuitivesurgical.com/

13. [Public Filings] Medtronic Annual Report | https://www.medtronic.com/

14. [Public Filings] Stryker Corporation Annual Report | https://investors.stryker.com/